Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 20/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7199969 | 0.88 | ELANE (0.87) | ELANE | |
| SCHEMBL3050184 | 0.86 | ELANE (1.00) | ELANE | |
| SCHEMBL7003495 | 0.86 | ELANE (1.00) | ELANE | |
| SCHEMBL29706324 | 0.86 | ELANE (1.00) | ELANE | |
| SCHEMBL7003169 | 0.86 | ELANE (1.00) | ELANE | |
| SCHEMBL7204887 | 0.85 | ELANE (0.80) | ELANE | |
| SCHEMBL7199752 | 0.80 | ELANE (0.68) | ELANE | |
| SCHEMBL7203045 | 0.79 | ELANE (0.82) | ELANE | |
| SCHEMBL7004601 | 0.79 | ELANE (1.00) | ELANE | |
| SCHEMBL9580699 | 0.78 | ELANE (1.00) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6656911-B2 | Oxadiazole ring structure peptoids which are useful as inhibitors of serine proteases | CORTECH, INC. | 2003-12-02 | — | — | US | claimed |
| US-20030203851-A1 | Substituted oxadiazole, peptoids which are useful for treating adult respiratory distress syndrome, septic shock and myocardial ischemia-reperfusion injury | CORTECH, INC. | 2003-10-30 | — | — | US | claimed |
| EP-0954526-A2 | SERINE PROTEASE INHIBITORS | CORTECH, INC. (US) | 1999-11-10 | — | — | EP | claimed |
| WO-1998024806-A2 | SUBSTITUTED OXADIAZOLE, THIADIAZOLE AND TRIAZOLE SERINE PROTEASE INHIBITORS | CORTECH, INC. (US) | 1998-06-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203851-A1 | Substituted oxadiazole, peptoids which are useful for treating adult respiratory distress syndrome, septic shock and myocardial ischemia-reperfusion injury | TNNI3, PEPD, STK35 | ELANE 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.